Den Europæiske Union - dansk - EMA (European Medicines Agency)

novo nordisk a/s - insulin detemir - diabetes mellitus - narkotika anvendt i diabetes - behandling af diabetes mellitus hos voksne, unge og børn i alderen 1 år og derover.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novo nordisk a/s - insulin aspart - diabetes mellitus - narkotika anvendt i diabetes - behandling af diabetes mellitus.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novo nordisk a/s - insulin aspart insulin degludec - diabetes mellitus - narkotika anvendt i diabetes - behandling af diabetes mellitus hos voksne, unge og børn fra 2 år.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novo nordisk a/s - insulin human - diabetes mellitus - narkotika anvendt i diabetes - behandling af diabetes mellitus.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin glargine, lixisenatide - diabetes mellitus, type 2 - narkotika anvendt i diabetes - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, type 2 - narkotika anvendt i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

elanco gmbh - tiamulin til veterinær anvendelse - injektionsvæske, opløsning - 200 mg/ml - svin

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmaménta aps - tiamulin til veterinær anvendelse - injektionsvæske, opløsning - 200 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

amgros i/s - thiaminhydrochlorid - injektionsvæske, opløsning - 100 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

amgros i/s - thiaminhydrochlorid - tabletter - 300 mg